UnknownNot Applicable

Flicker App for Minimal Hepatic Encephalopathy

United States75 participantsStarted 2019-10-22

Plain-language summary

There is a great unmet clinical need for improved screening for MHE in patients with cirrhosis. We will demonstrate that the Flicker-App can be used in clinic as well as at home by patients with cirrhosis to measure CFF, a proven screening test for MHE. We will optimize the protocol, software, and hardware of the Flicker-App to create a product appropriate for production and distribution to patients

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Cirrhosis (standard criteria) * Chronic liver disease Exclusion Criteria: * Grade III or IV hepatic encephalopathy * Mini-mental state examination score ≤25 (suggestive of dementia) * alcohol or illicit drug use within 3 months * current use of benzodiazepines * antiepileptics or psychotropic drugs * color blindness * severe vision impairment (blindness, macular degeneration).

What they're measuring

CFF Agreement

Timeframe: 1 day

Trial details

NCT IDNCT04415294

SponsorUniversity of Washington

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-05-31

Contact for this trial

Michael Yacoub

2067443402 yacoum@washington.medicine.edu

View on ClinicalTrials.gov More Hepatic Encephalopathy trials